Russia experiencing shortage of hemophilia B drugs

Russia is experiencing a shortage of drugs for patients with hemophilia B. Currently the most complex situation is observed in the case of both plasma-derived and recombinant coagulation factor IX which is the main replacement therapy for these patients, reports The Pharma Letter’s local correspondent.

The problem with recombinant factor IX is caused by difficulties with raw materials of the sole manufacturer - the Russian company Generium. At the same time the shortage of plasma-derived drugs is due to a supply interruption by one of the main manufacturers. As of now, in order to temporarily resolve the issue, the government plans to allow massive supplies of unregistered drugs to the market.